Wautier J L
Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris.
Presse Med. 1988 May 25;17(20):1037-40.
Platelet suppressive agents have been shown to improve the prognosis of coronary diseases such as myocardial infarction and unstable angina. Several markers of platelet activation during myocardial ischemia have been found to be increased. Platelet granule constituents (beta thromboglobulin or platelet factor 4) or thromboxane B2 have been reported to be enhanced and, in some studies, to be correlated with the ischemia. Molsidomine or its active metabolite SIN-1 have antithrombotic properties in experimental models. This effect seems to be at least partly related to their antiplatelet activities. SIN-1A inhibited platelet aggregation and release reaction. Specific investigations have demonstrated that SIN-1A acts at a early stage of platelet activation inhibiting calcium influx and phospholipase activity which lead to inhibition of thromboxane formation and fibrinogen binding. Antiplatelet properties were also observed after oral administration of molsidomine but the extent of inhibition appeared to vary with the subjects.
血小板抑制药物已被证明可改善冠心病（如心肌梗死和不稳定型心绞痛）的预后。现已发现心肌缺血期间血小板活化的几种标志物会增加。据报道，血小板颗粒成分（β-血小板球蛋白或血小板因子4）或血栓素B2会增加，并且在一些研究中与缺血相关。吗多明或其活性代谢产物SIN-1在实验模型中具有抗血栓形成特性。这种作用似乎至少部分与其抗血小板活性有关。SIN-1A抑制血小板聚集和释放反应。具体研究表明，SIN-1A在血小板活化的早期起作用，抑制钙内流和磷脂酶活性，从而抑制血栓素形成和纤维蛋白原结合。口服吗多明后也观察到了抗血小板特性，但抑制程度似乎因个体而异。
